Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.52 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM6B | O15054 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.31 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.31 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14486392 | 0.82 | DAO (0.51) | DAOCXCR2LMNAALDH1A1TP53 | |
| SCHEMBL14486330 | 0.81 | KDM6B (0.49) | DAOLMNAALDH1A1TP53RAB9A | |
| SCHEMBL14486064 | 0.77 | LMNA (0.42) | DAOLMNAALDH1A1TP53RAB9A | |
| SCHEMBL16001144 | 0.77 | HPGD (0.38) | DAOLMNAALDH1A1TP53RAB9A | |
| SCHEMBL16001134 | 0.77 | MMP13 (0.49) | DAOLMNAPOLBALDH1A1TP53 | |
| SCHEMBL14486051 | 0.77 | KDM6B (0.49) | DAOLMNAPOLBALDH1A1TP53 | |
| SCHEMBL14485964 | 0.77 | HPGD (0.50) | DAOLMNAPOLBALDH1A1MAPK1 | |
| SCHEMBL14485986 | 0.76 | DAO (0.50) | DAOALDH1A1TP53RAB9AKDM4C | |
| SCHEMBL14486459 | 0.76 | PLA2G7 (0.47) | DAOLMNAALDH1A1TP53RAB9A | |
| SCHEMBL14485971 | 0.75 | DAO (0.43) | DAOLMNAALDH1A1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10085986-B2 | Pyrimidinone compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-02 | — | — | US | disclosed |
| EP-2729453-B1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2015-05-06 | — | — | EP | disclosed |
| EP-2729453-B1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-04 | — | — | US | disclosed |
| WO-2013004995-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TPMT, DHFR, DPYD | DAO 934/4885CXCR2 229/4885LMNA 3191/4885 |
| US-10085986-B2 | Pyrimidinone compounds and their use | TPMT, DHFR, DPYD | DAO 934/4885CXCR2 229/4885LMNA 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.